BMO Capital upgraded Ionis Pharmaceuticals Inc (IONS) to Outperform from Market Perform on September 2, 2025. The stock is currently priced at $74.84.
This upgrade reflects a more optimistic outlook on Ionis Pharmaceuticals' prospects. The company's focus on developing and commercializing human therapeutic drugs using antisense technology positions it well within the biotechnology sector. Ionis markets several medicines, including TRYNGOLZA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, and WAYLIVRA, targeting conditions such as familial chylomicronemia syndrome and spinal muscular atrophy.
Ionis Pharmaceuticals has a market capitalization of $11.7 billion and reported an EPS of -1.71 for the trailing twelve months. Upcoming earnings are scheduled for July 28, 2026, with an estimated EPS of -0.74 and revenue of $214.6 million.
Analyst consensus indicates a Buy rating, with 11 Strong Buy, 13 Buy, and 7 Hold recommendations. Recent analyst actions include a maintenance of ratings by Goldman Sachs, Citigroup, and Barclays on September 3, 2025, alongside BMO's upgrade.
As always, analyst ratings are based on research and financial models and should be considered alongside other factors when making investment decisions.